COVID-19 VACCINE SAFETY AND EFFECTIVENESS
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: ChAdOx1 nCoV-19 vaccine (AZD1222)
- Registration Number
- NCT05133609
- Lead Sponsor
- Federal University of Espirito Santo
- Brief Summary
A longitudinal open-label study will include health professionals and patients with immune-mediated inflammatory diseases (IMID) who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-thrid dose), in the vaccination campaign against SARS-CoV-2 to assess the safety, efficacy and duration of the short- and long-term humoral and cellular immune response after vaccination for COVID-19 and compare the vaccine response between individuals who have or have not had previous SARS-Cov 2 infection.
- Detailed Description
A longitudinal open-label study that will include individuals who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-thrid dose), in the vaccination campaign against SARS-CoV-2 to assess the safety, efficacy and duration of the short- and long-term humoral and cellular immune response after vaccination for COVID- 19 and compare the vaccine response between individuals who have or have not had previous SARS-Cov 2 infection. Health professionals (HS) and patients with immune-mediated inflammatory diseases (IMID) who participate in vaccination campaigns at the Cassiano Antônio Mores da University Hospital will be included. Federal University of Espírito Santo (HUCAM-UFES). It is intended to include 200 health workers and 350 patients with IMID, totaling 550 participants. Participants who have had previous SARS-CoV-2 infection confirmed by RT-PCR or positive PRNT at baseline will be considered a group exposed to COVID-19 (CovPrev) and the group without previous infection will be considered a control group (Naive). The IMID group will include patients with Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Spondyloarthritis (SA), Sjögren's Syndrome (SS), Psoriasis (Pso), Inflammatory Bowel Disease (IBD) and Vasculitis (VASC) who complete validated international classification criteria for each disease. The criteria for vaccination in the IMID group will be in accordance with the National Immunization Program of the Ministry of Health (PNI/MS). Adverse events will be recorded during the first, second and fourth week, and through weekly telephone contacts until D40. The evaluations and collection of biological samples will be carried out in 5 moments (D0, D14 and D28 after the first dose; D28 after the second dose; and D28 after thrid dose) to evaluate the efficacy and in 3 moments (D180, D360 and D540), to evaluate the duration of immunity. Neutralization tests by plaque reduction (PRNT) will be performed to detect neutralizing antibodies against COVID-19, determination of the profile of specific IgM, IgA and IgG, dosage of systemic soluble factors (chemokines, cytokines and growth factors), characterization of phenotypes of immunoregulation, immunosenescence, cell activation and exhaustion and antigen-specific stimulation of peripheral blood mononuclear cells in vitro. The study hypothesis is that vaccine-induced production of neutralizing antibodies is more effective in individuals with previous natural SARS-Cov2 infection and less in immunosuppressed individuals.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 550
- Age 18 years or older
-
Pregnant women;
-
History of severe adverse reaction to any previously administered vaccine;
-
Having received another vaccine in the last 30 days.
- The criteria for vaccination in the immune-mediated inflammatory diseases (IMID) group will be in accordance with the Ministry of Health's National Immunization Program (PNI/MS).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Group 2 ChAdOx1 nCoV-19 vaccine (AZD1222) Patients with immune-mediated inflammatory diseases who will receive vaccine in the vaccination campaign against SARS-CoV-2. Group 1 ChAdOx1 nCoV-19 vaccine (AZD1222) Health professionals who will receive vaccine in the vaccination campaign against SARS-CoV-2.
- Primary Outcome Measures
Name Time Method Viral Neutralization Assay 24 months Neutralizing antibody titers will be expressed by the ability of antibodies to neutralize up to 50% the number of plaques (PRNT50). Title \> 1:50 will be considered positive.
- Secondary Outcome Measures
Name Time Method IgG (Immunoglobulin G) 24 months Determination of specific IgG profile. Results will be expressed in fluorescence intensity or pg/ml.
Lymphocyte investigation 18 months Investigation of memory T and B lymphocytes. The results will be expressed in percentage positive frequency for a specific cell phenotype.
IgM (Immunoglobulin M) 24 months Determination of specific IgM profile. Results will be expressed in fluorescence intensity or pg/ml.
IgA (Immunoglobulin G) 24 months Determination of specific IgA profile. Results will be expressed in fluorescence intensity or pg/ml.
Antigen-specific stimulation of peripheral blood mononuclear cells 18 months Antigen-specific stimulation of peripheral blood mononuclear cells in vitro. The results will be expressed in percentage positive frequency for a specific cell phenotype.
Adverse events 6 months All adverse events will be followed up to establish severity and causal correlation. There will be surveillance of deaths and will be reported to the ethics committee.
hospital admissions 24 months number of hospital admissions for covid-19
Cytokine investigation 18 months Investigation of intracytoplasmic cytokines. The results will be expressed in percentage positive frequency for a specific cell phenotype.
severe cases of COVID-19 24 months incidence of severe cases of COVID-19 over 20 months following treatment
intensive care unit (ICU) admissions 24 months number of intensive care unit (ICU) admissions for the treatment of SARS
systemic soluble factors 24 months Dosage of soluble systemic factors (chemokines, cytokines and growth factors). Results will be expressed in pg/ml.
deaths 24 months Number of deaths with specific ICD for covid-19
Trial Locations
- Locations (1)
Federal University of Espirito Santo
🇧🇷Vitoria, Espirito Santo, Brazil